tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

ILMNIllumina, Inc.

Health care · Lab Instruments · Nasdaq
Compare with peers → Embed
The 10-K against last year's

95 changes: 11 added, 17 removed, 64 reworded, 3 quiet changes

10-K Feb 12, 2026 vs Feb 12, 2025
Risk FactorsRedline ↓
13.5%
of the text changed · 10,483 words now
19.9%
of the text changed · 7,870 words now
Legal ProceedingsRedline ↓
52.5%
of the text changed · 2,155 words now
Accounting PoliciesRedline ↓
9.0%
of the text changed · 6,518 words now

10-K 0001110803-26-000024 (2026-02-12) vs 10-K 0001110803-25-000019 (2025-02-12)

The redline

The paragraph that changed most in each section

Marked against last year's 10-K: cut words struck through, new words highlighted and underlined.

MD&A 189 words changed in this paragraph; it is 39% similar to last year's version.
In 2024, 2025, the variance from the U.S. federal statutory tax rate of 21% was primarily because due to the release of a valuation allowance of $74 million against certain deferred tax assets in Singapore. This was partially offset by the implications of the $308 million income U.S. tax expense impact legislation that was signed on July 4, 2025, which included changes to no longer require capitalization of U.S. based research and development expenses. While the changes from the impairment recent U.S. tax legislation were favorable, based on available evidence, the increased U.S. tax deductions resulted in a determination that it is more likely than not the future realization of goodwill, which is nondeductible for deferred tax purposes, $90 million income tax expense impact of GRAIL pre-acquisition net operating losses on GILTI, the utilization of assets associated with certain U.S. foreign tax credits, and credits may not be achieved. Therefore, a valuation allowance of $62 million was recorded against the Pillar Two global minimum top-up tax, and the $52 million income deferred tax expense impact of capitalizing research and development expenses for assets associated with certain U.S. foreign tax purposes. credits. The income tax rate in 2024 2025 was favorably impacted by the $99 million income tax expense impact of the reversal of the European Commission fine related to the GRAIL acquisition, which is excluded from taxable income, and by the mix of earnings in jurisdictions with lower statutory tax rates than the U.S. federal statutory tax rate, such as in Singapore.

Source: Item 7, 10-K 0001110803-26-000024 vs Item 7, 10-K 0001110803-25-000019

Risk Factors 179 words changed in this paragraph; it is 73% similar to last year's version.
Furthermore, we have and may continue to become subject to stockholder inspection demands under Delaware law, investigations initiated by regulators and law firms, and derivative or other similar litigation that can be expensive, divert management attention and human and financial capital to less productive uses and result in potential reputational damage. The GRAIL acquisition and subsequent litigation resulted in in, among other things (i) the announcement of an investigation by the SEC and others by law firms of possible securities law violations; (ii) stockholder inspection demands seeking to investigate possible breaches of fiduciary duties, corporate wrongdoing or a lack of independence of the members of the Board, including a complaint filed in the Delaware Court of Chancery seeking to inspect books and records captioned Pavers and Road Builders Benefit Funds v. Illumina, Inc.; (iii) the filing of securities class actions in the United States District Court for the Southern District of California: Kangas v. Illumina, Inc. et al., Roy v. Illumina, Inc. et al., and Louisiana Sheriffs’ Pension & Relief Fund v. Illumina, Inc. et al.; (iv) the filing of a stockholder derivative complaint in the United States District Court for the Southern District of California captioned Warner v. deSouza et al.; (v) the filing of a stockholder derivative complaint in the United States District Court for the District of Delaware captioned Wang v. deSouza et al.; (vi) (ii) the filing of two securities class actions in the Superior Court of the State of California, County of San Mateo: Loren Scott Mar v. Illumina, et al. and Scott Zerzanek v. Illumina, Inc. et al.; (vii) (iii) the filing of a stockholder derivative and class action complaint captioned Icahn Partners LP, et al. v. deSouza, et al.; (viii) (iv) the filing of a stockholder derivative complaint captioned City of Omaha Police and Firefighters Retirement System v. deSouza, et al.; (ix) (v) the filing of a stockholder derivative complaint captioned City of Roseville General Employees Retirement System, et al. v. deSouza, et al.; and (x) the filing of a stockholder derivative complaint captioned Thomas P. DiNapoli v. John Thompson et al.; and (xi) (vi) the filing of a stockholder derivative complaint captioned Pavers and Road Builders Benefit Funds v. John Thompson et al. See note 9. Legal Proceedings within the Consolidated Financial Statements for further details. In the event that any of the matters described above result in one or more adverse judgments or settlements, we may experience an adverse impact on our financial condition, results of operations or stock price.

Source: Item 1A, 10-K 0001110803-26-000024 vs Item 1A, 10-K 0001110803-25-000019

Legal Proceedings 169 words changed in this paragraph; it is 54% similar to last year's version.
On February 26, 2024, a stockholder derivative complaint captioned City of Omaha Police and Firefighters Retirement System v. deSouza, et al., purportedly brought on behalf of Illumina, was filed in the Delaware Court of Chancery against certain current and former directors. On April 16, 2024, a stockholder derivative complaint captioned City of Roseville General Employees Retirement System, et al. v. deSouza, et al., purportedly brought on behalf of Illumina, was filed in the Delaware Court of Chancery against certain current and former directors and officers. On August March 26, 2024, the defendants filed a motion to dismiss the complaint in the lawsuit filed by City of Omaha Police and Firefighters Retirement System. On May 16, 2024, the defendants filed a stockholder derivative motion to dismiss the complaint captioned Thomas P. DiNapoli v. John Thompson et al., purportedly brought on behalf of Illumina, was filed in the Delaware Court lawsuit filed by City of Chancery against certain current and former directors. We are named as a nominal defendant in the complaints. The lawsuits allege the named directors and officers breached their fiduciary duties by knowingly causing Illumina to unlawfully close the GRAIL acquisition. The stockholders previously made requests to inspect certain books and records under Delaware law, and they purport to base their complaint in part on documents obtained from Illumina in response to those requests. Before the filing of the complaint, the purported stockholders did not make a demand that our Board of Directors pursue the claim asserted therein. The complaints seek damages against the individual defendants, costs and expenses, including attorney fees and other equitable relief. Roseville General Employees Retirement System, et al.

Source: Item 3, via Note 9 – LEGAL PROCEEDINGS, 10-K 0001110803-26-000024 vs Item 3, via Note 9 – LEGAL PROCEEDINGS, 10-K 0001110803-25-000019

Accounting Policies 128 words changed in this paragraph; it is 37% similar to last year's version.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) 2023-07, Segment Reporting - Improvements to Income Tax Reportable Segment Disclosures. The new standard requires a company to expand its existing income tax disclosures, specifically related disclose incremental segment information on an annual and interim basis, including significant segment expenses and measures of profit or loss that are regularly provided to the rate reconciliation and income taxes paid. CODM. The standard is does not change how an entity identifies its operating segments. The standard was effective for us beginning in fiscal year 2025, with early adoption permitted, 2024 and is expected interim periods within fiscal year 2025. We adopted the standard on its effective date in fiscal year 2024 and applied the amendments retrospectively to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2023-09 on all prior periods presented in the consolidated financial statements statements. See note 12. Segment and related disclosures. Geographic Information for additional details.

Source: Item 8, Note 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001110803-26-000024 vs Item 8, Note 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001110803-25-000019

Every change, by type

Sentences and paragraphs added, removed or reworded

Sentences and paragraphs of ILMN's Risk Factors and MD&A, 10-K 2026-02-12 against 10-K 2025-02-12. Each links to the text at sec.gov.

RemovedRisk Factors
As previously disclosed, the Acquisition was subject to various legal challenges, including by the FTC and European Commission. As a result, we have been a party to a number of regulatory and administrative proceedings regarding the Acquisition.

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedRisk Factors
result in one or more adverse judgments or settlements, we may experience an adverse impact on our financial condition, results of operations or stock price.

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedRisk Factors
products, and the prohibition of sale of any of our products or services could adversely affect our ability to grow or maintain profitability.

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedRisk Factors
In addition, if our products labeled as “For Research Use Only. Not for use in diagnostic procedures,” or RUO, are used, or could be used, for the diagnosis of disease, the regulatory requirements related to marketing, selling, and supporting such products could change or be uncertain, even if such use by our customers is without our consent. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected.

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedRisk Factors
In April 2024, the FDA issued the Final Rule relating to Laboratory Development Tests (LDTs). Newly developed LDT products may be subject to regulatory clearance or approval, and could result in adverse impacts to our business, financial condition, or results of operations.

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedRisk Factors
Certain of our in vitro diagnostic products, or IVDs, are currently available through laboratories that are certified under the Clinical Laboratory Improvements Amendments (CLIA) of 1988. These IVD products are commonly called “laboratory developed tests,” or LDTs.

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedRisk Factors
For a number of years, the FDA has exercised its regulatory enforcement discretion to not regulate LDTs as medical devices if created and used within a single laboratory. On April 29, 2024, the FDA released final regulations under 21 CFR Part 809 under the Federal Food, Drug, and Cosmetic Act (FD&C Act) amending the regulations to make explicit that LDTs offered as IVDs are devices under the FD&C Act including when the manufacturer of the IVD is a laboratory (the LDT Rule).

Read it in 10-K 2025-02-12 at sec.gov ↗

Show the other 7
RemovedRisk Factors
The LDT Rule also provides that the FDA intends to exercise enforcement discretion with regard to premarket review and most quality system requirements for certain categories of IVDs, including currently marketed IVDs offered as LDTs that were first marketed prior to April 29, 2024. The FDA has included additional enforcement discretion policies within the rule for LDTs approved by the New York State’s Clinical Laboratory Evaluation Program (NYS CLEP).

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedRisk Factors
The majority of revenue from products currently offered by our laboratories do not fall within the scope of the LDT Rule. With one exception, the LDTs currently offered as IVDs by our laboratories that fall within the purview of the LDT Rule are approved by NYS CLEP and were first marketed prior to the release of the LDT Rule.

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedRisk Factors
We cannot predict the specifics of how the FDA intends to implement the Final Rule and uncertainties remain as to whether and how newly developed LDT products that are now require regulatory clearance or approval may impact our business, financial condition, or results of operations.

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedRisk Factors
into our products, our information technology infrastructure and our products may in the future be, and have in the past been, impacted by cyber-attacks, employee error, malfeasance, or other disruptions.

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedMD&A
In September 2024, the European Commission withdrew its previously imposed fine of €432 million. Accordingly, we reversed the related accrual and recognized a net gain of $481 million in Q3 2024. The guarantees we provided in October 2023 to satisfy the obligation in lieu of cash payment while we appealed the European Commission’s jurisdictional and fine decisions are no longer outstanding. Refer to note 9. Legal Proceedings for additional details.

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedMD&A
In June 2024, we entered into a 364-day Delayed Draw Credit Facility, which provided us with a senior unsecured term loan credit facility in an aggregate principal amount of up to $750 million. On June 20, 2024, we borrowed $750 million on the Delayed Draw Credit Facility. The delayed draw term loan incurred interest at a rate of 6.7%. On September 9, 2024, we repaid the full principal amount outstanding under the Delayed Draw Credit Facility, as well as accrued interest, in an aggregate amount of $761 million and terminated the Delayed Draw Credit Agreement.

Read it in 10-K 2025-02-12 at sec.gov ↗

RemovedMD&A
The impact of the 2017 Tax Cuts and Jobs Act resulted in a one-time transition tax on earnings of certain foreign subsidiaries which we elected to pay in installments. As of December 29, 2024, we owed $39 million, which we expect to pay within the next year.

Read it in 10-K 2025-02-12 at sec.gov ↗

Next Related parties →